OTC : LABFF

Laboratorios Farmaceuticos Rovi, S.A.

$90.61 USD

$0 (0.0%)

Volume
100
Average Volume
89
Market Capitalization
$4.63B
P/E Ratio
22.22
Dividend Yield
1.68%
Price Target
Year High
$90.61
Year Low
$90.61
Day High
—
Day Low
—
Payout Ratio
$0.36
Current Ratio
$3.66
Company Overview

OTC

Juan Lopez-Belmonte Encina

Drug Manufacturers - Specialty & Generic

Healthcare

LABFF

2232

ES

USD

https://www.rovi.es

34 91 021 30 00

N/A

0002029970

Liquidity Metrics

0.17

3.66

1.80

0.66

0.36

Sales & Valuation

$743.2M

3.94

4.33

25.44

2.24

Profitability

$2.75

$140.39M

17.79%

23.30%

20.89%

14.23%

P/E Metrics

22.22

-0.62

-0.62

Analyst Price Target & Rating

Buy

4/5

2 Analysts

%

Financial Health Scores

12.93

5/9

$393.24M

$929.83M

$240.49M

$175.62M

Key Metrics (TTM)

$2.78B

3.75

13.91

3.66

20.89%

15.99%

4.77%

4.15%

$27.64

347 days

Company Executives
Name Title
Juan Lopez-Belmonte Encina Chairman & Chief Executive Officer
Miguel Ángel Ortega Sánchez Chief Industrial Officer
Rosario Perucha Pérez Marketing Director
María Álvarez Solas Chief Operating Officer
Marta Campos Martínez Head of Investor Relations
Mercedes Benítez del Castillo Sánchez Chief Legal Officer
Ivan Jorge Lopez-Belmonte Encina Second Deputy Chairman and Chief Commercial & Development Officer
Javier Lopez-Belmonte Encina First Deputy Chairman, GM of Industrial Operations & Chief Financial Officer
Alicia Hurtado Morales Chief Compliance Officer
Francisco Javier Angulo García Human Resources Manager
Poll Results

No votes yet today — be the first to share your view!

About Laboratorios Farmaceuticos Rovi, S.A. (OTC:LABFF) Stock

Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical firm actively involved in the discovery, creation, manufacturing, and commercialization of medicinal products. Its market presence extends across Spain, the European Union, OECD nations, and other international territories. Beyond its proprietary portfolio, Rovi also distributes pharmaceutical offerings under license from other companies. Rovi's diverse product lineup addresses several critical health conditions. Key offerings include Hibor and Becat (an Enoxaparin biosimilar), both low-molecular-weight heparins employed in preventing and managing venous thromboembolic disorders. Neparvis targets symptomatic chronic heart failure with reduced ejection fraction in adults. For hypercholesterolemia, the company offers Absorcol, Vytorin ... , and Orvatez. Respiratory ailments like chronic obstructive pulmonary diseases (COPD) are treated with long-acting bronchodilators such as Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is prescribed for men experiencing moderate to severe storage and voiding symptoms due to benign prostatic hyperplasia (BPH) who have not responded sufficiently to single-drug therapies. Additionally, Medikinet and Medicebrán provide treatment for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent populations. The firm also supplies a range of specialized hospital products for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventional procedures, Multihance and Prohance for MRI, and Sonovue for ultrasound examinations. Furthermore, Rovi provides advanced contrast injection systems, including EmpowerCTA+, EmpowerMR, and CT Exprès, along with their associated disposable components. Its portfolio extends to over-the-counter (OTC) pharmaceutical products. Moreover, Rovi offers contract development and manufacturing organization (CDMO) services to external businesses, producing pharmaceuticals in diverse forms such as prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi caters to a broad spectrum of healthcare stakeholders, encompassing wholesalers, physicians, nurses, pharmacists, and directly, patients. A notable partnership exists with Moderna, Inc., where Rovi is involved in the manufacturing of mRNA COVID-19 vaccine candidates. Established in 1946 and headquartered in Madrid, Spain, Laboratorios Farmaceuticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.

Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q1 2026 Earnings Call Transcript

2026-05-09 11:41:14

Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q1 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Laboratorios Farmaceuticos Rovi, S.A. (LABFF) stock price?

Laboratorios Farmaceuticos Rovi, S.A.(OTC:LABFF) stock price is $90.61 in the last trading session. During the trading session, LABFF stock reached the peak price of $90.61 while $90.61 was the lowest point it dropped to. The percentage change in LABFF stock occurred in the recent session was 0.0% while the dollar amount for the price change in LABFF stock was $0.

LABFF's industry and sector of operation?

The OTC listed LABFF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of LABFF?

Juan Lopez-Belmonte Encina | Chairman & Chief Executive Officer
Miguel Ángel Ortega Sánchez | Chief Industrial Officer
Rosario Perucha Pérez | Marketing Director
María Álvarez Solas | Chief Operating Officer
Marta Campos Martínez | Head of Investor Relations

How many employees does LABFF have?

Number of LABFF employees currently stands at 2232. LABFF operates from Calle José Isbert, 2, Madrid, MA 28223, ES.

Link for LABFF official website?

Official Website of LABFF is: https://www.rovi.es

How do I contact LABFF?

LABFF could be contacted at phone #34 91 021 30 00 and can also be accessed through its website. LABFF operates from Calle José Isbert, 2, Madrid, MA 28223, ES.

How many shares of LABFF are traded daily?

The average number of LABFF shares traded daily for last 3 months was 89.

What is the market cap of LABFF currently?

The market value of LABFF currently stands at $4.63B with its latest stock price at $90.61